An anti-TROP2 antibody–drug conjugate binds TROP2 on tumor cells, is internalized, and releases a cleavable topoisomerase I inhibitor (tirumotecan) intracellularly, causing DNA damage/replication stress and apoptosis, with potential bystander killing of neighboring cells.